CMS Finalizes Guidance on Medicare Part D Manufacturer Discount Program
The FDA Law Blog
DECEMBER 3, 2023
Each phase-in policy allows eligible manufacturers to build up in a stepwise manner to the 10% and 20% applicable discounts by 2029 and 2031, respectively. Its total expenditures for all specified drugs that are single source drugs or biologics for which payment may be made under Part B in 2021 represented less than 1.0%
Let's personalize your content